Central Nervous System Stimulant Drugs Industry

Central Nervous System (CNS) Stimulant Drugs Market Analysis

The Central Nervous System Stimulant Drugs Market size is estimated at USD 11.71 billion in 2025, and is expected to reach USD 15.97 billion by 2030, at a CAGR of 6.39% during the forecast period (2025-2030).

• The significant factor attributing to this market's growth is CNS disorders such as sleep apnea, narcolepsy, and attention deficit hyperactivity disorder, which have witnessed a substantial rise in recent years. According to a study published in the American Thoracic Society in 2022, obstructive sleep apnea (OSA) has a global prevalence of over 22.6%. The expanding senior population significantly impacts the CNS stimulant drugs market. The aged individual has a high risk of developing central nervous system issues such as sleeping disorders and ADHD, which require CNS stimulant drugs for their effective management. Over 20% of the elderly population have a state of sleep apnea and daytime sleepiness.
• For instance, according to Sleep Care Online, the shape of sleep apnea in elderly patients aggravates the pre-existing medical conditions common in older patients, including hypertension, cardiovascular issues, and diabetes. For instance, according to the data published by the World Health Organization in October 2022, it is estimated that by 2030, 1 in 6 people worldwide will be aged 60 years or over. The share of the population aged 60 years and over will increase to 1.4 billion in 2030; by 2050, the number of people aged 60 years and older will double to 2.1 billion. It was also estimated that the number of persons aged 80 years or older is expected to triple by 2050 to reach 426 million.
• According to the January 2023 World Social Report, the number of adults aged 65 and older is expected to more than quadruple between 2021 and 2050, increasing from 761 million to 1.6 billion. The number of people aged 80 years or older is growing even faster. Thus, the expanding geriatric population is anticipated to boost the demand for CNS stimulant drugs, which will boost the growth of the market in the coming years.
• The strategic activities taken by the market players, such as product launches, mergers, and acquisitions, are expected to contribute to market growth during the forecast period. For instance, in August 2022, Tris Pharma Inc. launched its Dyanavel XR, which is an amphetamine extended-release tablet intended for oral use for the treatment of attention deficit hyperactivity disorder.
• Therefore, owing to the factors above, the market is anticipated to grow during the forecast period. However, numerous side effects of drugs are expected to hinder the market's growth during the forecast period.

Central Nervous System (CNS) Stimulant Drugs Market Trends

The Attention Deficit Hyperactivity Disorder Segment is Expected to Witness Significant Growth During the Forecast Period

• The attention deficit hyperactivity disorder segment is expected to hold a significant market share in the central nervous system (CNS) stimulant drugs market during the forecast period. Factors such as the rising prevalence of attention deficit hyperactivity disorder among children and adolescents and the easy availability of treatment drugs such as CNS stimulants will likely propel the segment growth during the forecast period.
• For instance, per the data published by the National Health Insurance Corporation of South Korea in March 2023, the number of individuals diagnosed with attention deficit hyperactivity disorder (ADHD) increased in the past few years, reaching 102,322 in 2022. Further, as per the Centers for Disease Control and Prevention (CDC), in 2022, the approximate number of children detected with attention deficit hyperactivity disorder was 6.1 million, with a prevalence rate of 9.4%.
• Additionally, the increasing prescription rate for ADHD treatment using CNS stimulants is expected to contribute to the market growth during the forecast period. For instance, according to the National Health Institute, in July 2023, the prescription of CNS stimulants and ADHD medications rose by 32% among adults aged 18 and above and 12% in children under 17 during 2022-2023. This increase highlights a growing trend in the treatment of ADHD and other related conditions in both age groups. Thus, increasing the prescription rate for ADHD treatment will contribute to the segment growth during the forecast period.
• Therefore, the attention deficit hyperactivity disorder segment is expected to witness significant growth during the forecast period due to the factors, including the rising prevalence of attention deficit hyperactivity disorder.

North America is Expected to Witness Significant Growth During the Forecast Period

• During the forecast period, North America is expected to experience significant growth in the central nervous system (CNS) stimulant drugs market.
• The development of the central nervous system (CNS) stimulant drugs market is driven by the high healthcare expenditure, high prevalence of central nervous system diseases, expanding geriatric population, and presence of leading market players in the region. For instance, as per the data published by the Centre for ADHD Awareness Canada (CADDAC) in 2023, ADHD is one of Canada's most common neurodevelopmental disorders, affecting over 1.8 million Canadians. Several clinical trials are ongoing in North America, especially in the United States. More than half of the total neurological disease clinical studies conducted worldwide are in the United States.
• Also, according to a research study published in the British Medical Journal in 2022, approximately 4.1 million United States adults reported prescriptions for CNS stimulant drugs. The same source reported that the growth rate of the total number of prescriptions dispensed was about 96%, and significant percentage increases occurred in adults aged 25 years and older.
• Therefore, owing to the factors above, the growth of the market is anticipated in North America.

Central Nervous System (CNS) Stimulant Drugs Market Industry Overview

The central nervous system (CNS) stimulant drugs market is moderately competitive due to the presence of several companies operating globally and regionally. The competitive landscape includes an analysis of some international and local companies that hold market shares and are well known, including Ironshore Pharmaceuticals Inc., Novartis AG, Takeda Pharmaceutical Co. Ltd, Azurity Pharmaceuticals Inc., Noven Therapeutics LLC, Independence Pharmaceuticals, Janssen Pharmaceuticals Inc., Elite Pharmaceuticals Inc., Kempharm Inc., and Adlon Therapeutics LP.

Central Nervous System (CNS) Stimulant Drugs Market Leaders

Central Nervous System (CNS) Stimulant Drugs Market News

• May 2024: Tris Pharma Inc. received FDA approval for ONYDA XR (clonidine hydrochloride), an extended-release oral suspension designed for once-daily administration at night. This approval is specifically for treating ADHD in pediatric patients aged six and above, either as a standalone therapy or in conjunction with approved CNS stimulant medications.
• May 2024: The FDA approved Onyda XR, an extended-release oral suspension of clonidine hydrochloride, for the treatment of ADHD in pediatric patients aged six years and older. This medication can be used either as a monotherapy or as an adjunctive therapy to an approved central nervous system stimulant.